Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fennec Pharmaceuticals Inc. - Common Stock (NQ:FENC)

7.980 +0.140 (+1.79%)
Streaming Delayed Price Updated: 10:19 AM EDT, Aug 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fennec Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 Next >
Stocks Rise as "Fear Gauge" Cools Off
The Dow Jones Industrial Average and Nasdaq Composite are both up triple digits midday, paring some of their losses from Friday's massive selloff. 
Via Talk Markets
Topics Stocks
Mid-Day Market Update: Crude Oil Rises 4%; Fennec Pharmaceuticals Shares Slide
Midway through trading Monday, the Dow traded up 0.30% to 35,005.10 while the NASDAQ climbed 1.39% to 15,707.48. The S&P also rose, gaining 0.97% to 4,639.11. The U.S. has the... 
Via Benzinga
Topics Stocks
33 Stocks Moving In Monday's Mid-Day Session
Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares jumped 116.4% to $86.13 after the company announced positive topline results from the GEM-3 Phase 3 trial of investigational... 
Via Benzinga
Why Fennec Pharmaceuticals's Stock is Trading Higher Today
Fennec Pharmaceuticals's Stock Price And Volume Action Fennec Pharmaceuticals's (NASDAQ: 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; Li Auto Sales Top Views
Following the market opening Monday, the Dow traded up 0.22% to 34,977.01 while the NASDAQ climbed 1.53% to 15,727.94. The S&P also rose, gaining 0.92% to 4,637.03. The U.S.... 
Via Benzinga
Topics Stocks
Fennec Pharma Stock Plunges On Expected FDA CRL For Pedmark For Chemo-Induced Hearing Issues
Fennec Pharmaceuticals Inc (NASDAQ: FENC) said it expects to receive a Complete Response Letter (CRL) from the FDA regarding its marketing application for Pedmark... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
I hope you got your rest out over the holiday weekend because we're starting off Monday with the biggest pre-market stock movers! 
Via InvestorPlace
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting... 
Via Talk Markets
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the... 
Via Benzinga
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... 
Via Benzinga
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21) Agios Pharmaceuticals, Inc... 
Via Benzinga
Fennec Pharma Stock Is Trading Higher As Pedmark Is Under FDA Review For Chemo-Induced Toxicity
The FDA has accepted for review Fennec Pharmaceuticals Inc's (NASDAQ: FENC) resubmitted marketing application seeking approval for Pedmark (formulated sodium... 
Via Benzinga
Fennec Pharma Refiles Pedmark US Application For Cisplatin-Induced Ototoxicity In Pediatric Patients
Fennec Pharmaceuticals Inc (NASDAQ: FENC) has resubmitted its marketing application to the FDA seeking approval for Pedmark (formulated sodium thiosulfate) for the... 
Via Benzinga
The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27) BioCryst Pharmaceuticals,... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2021
Upgrades For Cerecor Inc (NASDAQ:CERC), Maxim Group upgraded the previous rating of Hold to Buy. In the fourth quarter, Cerecor showed an EPS of $0.19, compared to $0.10... 
Via Benzinga
51 Biggest Movers From Yesterday
Gainers UTime Limited (NASDAQ: UTME) shares jumped 875% to close at $39.00 on Tuesday after the company priced its IPO at $4 per share. Romeo Power, Inc. (NYSE: RMO) climbed 59.6... 
Via Benzinga
Topics Initial Public Offering
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.